Honesty is fundamental,Quality is life,lnnovation is power, and Service is soul!

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsCancer Cure Drug

Everolimus (RAD001) for Research 159351-69-6 Breast cancer Pancreatic cancer

Good quality Anti Aging Drugs for sales
Good quality Anti Aging Drugs for sales
Hello linda, It is very nice to collaboration with you. Your powder and your service are very good. I admire your work. Thanks again.

—— —— Armando From the Italy

I have done business with this company many times. Very happy with quality. It is a very good deal.

—— —— Mark From the USA

Shipment is always quick and safe. Definitely will do more business with them.

—— —— Tom From the UK

One of my friend bought products from this company and highly recommended it. Really satisfied with their after-sale service. Very quick response.

—— —— Robert From the Spain

The test with sodium 3-nitrobenzenesulphonate are positives, I´m satisfied with the product, I contact you whent I need it more.

—— —— Mr. RAUL From Canada

I'm Online Chat Now

Everolimus (RAD001) for Research 159351-69-6 Breast cancer Pancreatic cancer

China Everolimus (RAD001)  for Research 159351-69-6 Breast cancer Pancreatic cancer supplier
Everolimus (RAD001)  for Research 159351-69-6 Breast cancer Pancreatic cancer supplier Everolimus (RAD001)  for Research 159351-69-6 Breast cancer Pancreatic cancer supplier Everolimus (RAD001)  for Research 159351-69-6 Breast cancer Pancreatic cancer supplier

Large Image :  Everolimus (RAD001) for Research 159351-69-6 Breast cancer Pancreatic cancer

Product Details:

Place of Origin: China
Brand Name: Jusheng Brand
Certification: ISO, 9001, USP
Model Number: 159351-69-6

Payment & Shipping Terms:

Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Contact Now
Detailed Product Description
CAS: 159351-69-6 Alias: Everolimus , RAD001
Apparence: Almost White Crystalline Powder Purity: 99.5%
Stock: Enough Stock Grade: Pharma Grade

Everolimus (RAD001) for Research 159351-69-6 Breast cancer Pancreatic cancer

Quick detail

Drug Type: Everolimus is a targeted therapy and is classified as an mTOR inhibitor.
Everolimus CAS 159351-69-6 Brand: NEWBIO
MW: 958.22 MSDS: Inavaiable
MF:C53H83NO14 Sample: Avaiable
Category: API Min order: 10grams
Quality standard: 99.50% HPLC Place of Origin:China

Appearance Everolimus is a macrolide derived from Rapamycin (sc-3504) and shown to inhibit cell proliferation induced by growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that Everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.
Applications Pharmaceutical raw materials An inhibitor of FRAP (mTOR)

Basic information

Jusheng Packing: 1)Aluminum Foil Bag: 100g, 500g, 1Kg 2)Fiber Drum: 25Kg
Jusheng Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Jusheng Clearance Rate: 100% Custom Pass, Diguised Package and Safe Delivery
Jusheng Delivery Time: 5-14 Working Days, Tracking Number Available
Jusheng Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Jusheng Origin: Hubei Province, China
Jusheng Brand Name: Jusheng Brand
Jusheng Production Capacity:  1000Kg/Month

Everolimus Description

Everolimus is a Kinase Inhibitor. It’s brand name is Afinitor. Everolimus is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties.The mechanism of action of everolimus is as a Protein Kinase Inhibitor, and Cytochrome P450 3A4 Inhibitor, and P-Glycoprotein Inhibitor, and Cytochrome P450 2D6 Inhibitor.
In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.

Everolimus is a biological therapy treatment for

Advanced breast cancer if you have been through the menopause (post menopausal). You take it with the hormone therapy drug exemestane
Advanced kidney cancer that has come back either during or after treatment.
Neuroendocrine tumours of the pancreas that can't be removed with surgery or have spread (metastatic disease).
Researchers are also looking at everolimus as a treatment for head and neck cancer and cancer of the food pipe (oesophageal cancer).

Everolimus approved indications

  • Everolimus is approved to treat:
  • Breast cancer. It is used in combination with exemestane in postmenopausal women with advanced hormone receptor positive (HR+) breast cancer that is also HER2 negative (HER2-) and has not gotten better with other chemotherapy.
  • Pancreatic cancer, gastrointestinal cancer, and lung cancer (certain types). It is used in adults with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body).
  • Renal cell carcinoma (a type of kidney cancer) that is advanced, in adults who have not gotten better with other chemotherapy.Subependymal giant cell astrocytoma in adults and children who have tuberous sclerosis and are not able to have surgery. Everolimus is available as tablets (Afinitor) or tablets for oral suspension (Afinitor Disperz). Only Afinitor Disperz is used in children.
  • The use of everolimus to treat cancer is approved for the Afinitor brand. Everolimus is also approved to treat transplant rejection. This use is approved for the Zortress brand.
  • Everolimus is also being studied in the treatment of other types of cancer.

Attention pls 

Stop using Everolimus (Afinitor) and call your doctor at once if you have:

  1. new or worsening cough, chest pain, wheezing, feeling short of breath;
  2. signs of infection--fever, chills, joint pain, red or swollen gums, painful mouth sores, skin sores, rapid heart rate, pale skin, easy bruising, unusual bleeding, feeling light-headed;
  3. kidney problems--little or no urination; painful or difficult urination; swelling in your feet or ankles; feeling tired or short of breath;
  4. liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  5. any wound that will not heal; or
  6. a surgical incision that is red, warm, swollen, painful, bleeding, or oozing pus.


Related products:

Tofacitinib cas no.540737-29-9
Posaconazole cas no.171228-49-2
Ramelteon cas no.196597-26-9
Sofosbuvir cas no.1190307-88-0
Doclatasvir Dihydrochloride cas no.1009119-65-6
Ledipasvir Gs588 cas no.1256388-51-8
Asunaprevir cas no.630421-48-6
Vorapaxar cas no.618385-01-6
vildogliptin cas no.274901-16-5

Contact Details
Hubei Jusheng Technology Co., Ltd.

Contact Person: linda

Send your inquiry directly to us (0 / 3000)